NCT01740687已完成不适用
A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 211
- 主要终点
- Number of Pregnancies at 1-year Time Point (1-year Pregnancy Rate)
研究概览
简要总结
The purpose of the post approval study is to evaluate the effectiveness and safety of the Essure System when a NovaSure Endometrial Ablation procedure is performed following a successful Essure Confirmation Test.
详细描述
This study has previously been posted by Conceptus, Inc. After acquiring Conceptus, Inc., Bayer is now the sponsor of the trial.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •All inclusion criteria from the Essure Permanent Birth Control System Instructions for Use and/or the NovaSure Impedance Controlled Endometrial Ablation (EA) System Instructions for Use and Controller Operator's Manual will apply.
- •Women experiencing menorrhagia due to benign causes
- •Women who are relying on the Essure micro-inserts for permanent contraception following a successful Essure Confirmation Test (as applicable to the Post Approval Study)
- •Women willing to accept the risk of pregnancy while relying on the Essure micro-inserts for prevention of pregnancy following a NovaSure ablation procedure for menorrhagia
排除标准
- •All exclusion criteria from the Essure Permanent Birth Control System Instructions for Use and/or the NovaSure Impedance Controlled Endometrial Ablation System Instructions for Use and Controller Operator's Manual will apply.
- •Women who previously underwent a fallopian tube sterilization procedure (other than Essure placement)
- •Women who present with any other medical complaints, conditions or symptoms unrelated to the Essure System and/or subsequent NovaSure EA including, but not limited to:
- •Gynecological co-morbidities (e.g., pelvic infection, cervicitis, undiagnosed vaginal bleeding, endometrial cancer, myomas, and polyps)
- •Reproductive tract anatomical variants and/or pathology which could make the subject unsuitable for the Essure and/or NovaSure transcervical procedures
- •Women currently wearing an intrauterine device and unwilling to have it removed before NovaSure
结局指标
主要结局
Number of Pregnancies at 1-year Time Point (1-year Pregnancy Rate)
时间窗: 1 year after NovaSure Endometrial Ablation procedure
Number of Pregnancies at 3-year Time Point (3-year Pregnancy Rate)
时间窗: 3 years after NovaSure Endometrial Ablation procedure
次要结局
- Number of Adverse Events (AEs) When NovaSure Endometrial Ablation Was Performed in the Presence of Essure Inserts(After 3-year follow-up)
研究者
相似试验
已完成
不适用
The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in WomenContraceptionNCT01861886Bayer73
撤回
不适用
A Safety and Effectiveness Study of the Supira System in Patients Undergoing HRPCI - CE StudyVentricular Assist DeviceNCT06565039Supira Medical135
已完成
不适用
SureScan Post-Approval StudyBradycardiaNCT01299675Medtronic2,483
已完成
2 期
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian CancerOvarian NeoplasmsNCT00772863Sanofi37
已完成
不适用
Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling DeviceTraumatic Brain InjuryNCT02420639Advanced Cooling Therapy, Inc., d/b/a Attune Medical12